[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Dean et al., 2018 - Google Patents

The use of NLR, PLR and CA19. 9 as prognostic markers for locally advanced pancreatic cancer

Dean et al., 2018

View PDF
Document ID
5959202699632875841
Author
Dean A
Higgs D
Das A
Fennessy S
Rogers-Seeley M
McGarvey C
McNulty M
Publication year
Publication venue
Annals of Oncology

External Links

Snippet

Methods: A retrospective cohort study was conducted for 66 patients with locally advanced pancreatic cancer who received chemotherapy only (C), chemotherapy plus radiotherapy (CRT) or chemotherapy plus radiotherapy then surgery (CRTS) between January 2014 and …
Continue reading at www.annalsofoncology.org (PDF) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds

Similar Documents

Publication Publication Date Title
US11229689B2 (en) Methods of cancer treatment using activated T cells
Papadatos-Pastos et al. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
He et al. Biomarkers and future perspectives for hepatocellular carcinoma immunotherapy
Chung et al. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer
Yang et al. Immunotherapy with immune checkpoint inhibitors for advanced colorectal cancer: a promising individualized treatment strategy
Dean et al. The use of NLR, PLR and CA19. 9 as prognostic markers for locally advanced pancreatic cancer
EP3313431B1 (en) Method for inducing early t memory response with short peptides anti-tumor vaccine
Sun et al. Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer
Ascierto et al. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)
BR112021014657A2 (en) METHODS TO TREAT PROSTATE CANCER BASED ON MOLECULAR SUBTYPES
Li et al. 34th annual meeting & pre-conference programs of the society for immunotherapy of cancer (SITC 2019): part 2
Yusuf et al. Antibodies matter: A meta-analysis of the prognostic value of human equilibrative nucleoside transporter 1 (hENT1) antibodies in pancreatobiliary cancer
Paliogiannis et al. Blood cell count indexes of systemic inflammation as predictive biomarkers of immunotherapy outcomes in advanced non-small-cell lung cancer
Hack et al. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1
Sundar et al. Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes
Shatara et al. ATRT-21. Rhabdoid predisposition syndrome: report of molecular profiles and treatment approach in three children with synchronous atypical teratoid/rhabdoid tumor and malignant rhabdoid tumor
Park et al. 8/# 234 Immune properties of tumor-infiltrating lymphocytes in ovarian clear cell carcinoma relative to ovarian high-grade serous carcinoma
Finetti et al. ATRT-25. INTEGRATED QUANTITATIVE SWATH-MS PROTEOMICS ANALYSIS OF ATRTs UNCOVERS NEW THERAPEUTIC OPPORTUNITIES
Cui et al. Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy
Jang et al. Comparing efficacy of 1-L Peg-Asc with prucalopride versus 2-L Peg-Asc for bowel preparation
CN111316101B (en) Predicting responders to cyclophosphamide therapy
Mao et al. Weijie Ma1, 2†, Sixi Wei1†, Siqi Long1, Eddie C. Tian1, Bridget McLaughlin3, Maria Jaimes 4, Dennis J. Montoya5, Varun R. Viswanath1, Jeremy Chien5, Qianjun Zhang6, Jonathan E. Van Dyke3, Shuai Chen 7 and Tianhong Li1, 8
Jeon et al. Endoscopic detachable auxiliary manipulator in endoscopic submucosal dissection: Animal model studY
Wang The Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitor in≥ 3 line MSS Metastatic Colorectal Cancer Patients
NAG et al. Species Contribution Reference Number